Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03167255 · ClinicalTrials.gov registry record · Phase 2
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase 2 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 6
- Study locations
NCT03167255: Completed Phase 2 study of Duchenne Muscular Dystrophy, sponsored by NS Pharma.
NCT03167255 is a Phase 2 study of Duchenne Muscular Dystrophy that has completed, run by NS Pharma. The registered enrollment target is 16 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03167255, a Phase 2 study of Duchenne Muscular Dystrophy, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
Primary Outcome
A primary efficacy endpoint was compared to Baseline of Study 201 (NCT02740972): Time to Stand (TTSTAND)
Conditions Studied
Interventions
- DRUG NS-065/NCNP-01
Study Locations (6)
California
- UC Davis - Sacramento
Illinois
- Lurie Children's Hospital - Chicago
Missouri
- Washington University - St Louis
North Carolina
- Duke University Medical Center - Durham
Virginia
- Children's Hospital of Richmond at VCU - Richmond
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
What the finished NCT03167255 record still lists
NCT03167255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which NS-065/NCNP-01 is the first listed.
NCT03167255 lists 6 locations in 6 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT03167255 about?
NCT03167255 is a clinical study titled "Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)". This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
What is the current status of trial NCT03167255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-07-06. Estimated completion is 2021-11-15.
What conditions does trial NCT03167255 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT03167255?
The interventions under investigation include: NS-065/NCNP-01 (DRUG).
Who is sponsoring clinical trial NCT03167255?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03167255 being conducted?
This trial has 6 study locations across California, Illinois, Missouri, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03167255's enrollment target sits among peer trials
16 38th of 48 higher than 11 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI